CLNPHARMA
Research CLNPHARMA (CLN.WA) on Bullrun: market cap PLN 1.01B, P/E 9.2. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCLN.WA
- ExchangeXWAR
- CountryPoland
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyPLN
- Market capPLN 1.01B
- P/E9.2
- Financial periodQ1 2026
- RevenuePLN 56.93M
- Net incomePLN 162.60M
- Free cash flow-PLN 19.22M
- Gross margin70.7%
Valuation Snapshot
latest market cap is PLN 1.01B; P/E is 9.2.
Peer valuation comparison
Latest P/E is 9.17x versus a Healthcare sector median of 24.64x (62.8% below).
Latest P/E is 9.17x versus a Poland median of 12.32x (25.6% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | n/a | -PLN 79.08M | PLN 23.85M | n/a | n/a | PLN 1.27M | PLN 14.19M | PLN 363.25M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-10 | PLN 1.01B | 9.2 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 PLN.
About CLNPHARMA
Celon Pharma S.A., an integrated pharmaceutical company, engages in the research, manufacture, and marketing of specialised generic products. The company provides drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders. Celon Pharma S.A. was founded in 2002 and is based in Lomianki, Poland. The company operates as a subsidiary of Glatton Sp. z o.o.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is CLNPHARMA's market cap?
CLNPHARMA's market capitalization is PLN 1.01B.
What is CLNPHARMA's P/E ratio?
CLNPHARMA's price-to-earnings (P/E) ratio is 9.2.
What does CLNPHARMA do?
Celon Pharma S.A., an integrated pharmaceutical company, engages in the research, manufacture, and marketing of specialised generic products. The company provides drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders. Celon Pharma S.A. was founded in 2002 and is based in Lomianki, Poland. The company operates as a subsidiary of Glatton Sp. z o.o.